Lawson Kroeker Investment Management Inc. NE increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 120,922 shares of the biopharmaceutical company’s stock after acquiring an additional 34 shares during the period. Gilead Sciences comprises approximately 2.9% of Lawson Kroeker Investment Management Inc. NE’s holdings, making the stock its 14th largest position. Lawson Kroeker Investment Management Inc. NE’s holdings in Gilead Sciences were worth $8,559,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Parnassus Investments CA raised its stake in Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Gilead Sciences by 9.8% during the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its stake in Gilead Sciences by 75.0% during the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after buying an additional 1,092,206 shares during the last quarter. AQR Capital Management LLC raised its stake in Gilead Sciences by 25.7% during the 1st quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after buying an additional 1,066,172 shares during the last quarter. Finally, Swiss National Bank raised its stake in Gilead Sciences by 26.9% during the 1st quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock valued at $317,059,000 after buying an additional 989,400 shares during the last quarter. Institutional investors own 73.97% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Position Boosted by Lawson Kroeker Investment Management Inc. NE” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-position-boosted-by-lawson-kroeker-investment-management-inc-ne/1578541.html.

A number of brokerages have weighed in on GILD. Leerink Swann reiterated a “market perform” rating and set a $87.00 target price (up from $82.00) on shares of Gilead Sciences in a research note on Wednesday. Royal Bank Of Canada began coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They set an “outperform” rating and a $94.00 target price for the company. ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Eleven research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $84.29.

Shares of Gilead Sciences, Inc. (GILD) traded up 0.2381% during mid-day trading on Thursday, hitting $82.8368. 3,013,809 shares of the stock traded hands. The firm has a 50 day moving average of $77.54 and a 200 day moving average of $70.38. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a market cap of $108.18 billion, a P/E ratio of 8.9972 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter last year, the business earned $3.08 earnings per share. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post $8.78 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

In related news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the transaction, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. In the last quarter, insiders sold 466,819 shares of company stock worth $36,740,240. Company insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.